Clinical trials: Congenital Adrenal Hyperplasia
Congenital Adrenal Hyperplasia, CAH - Congenital Adrenal Hyperplasia
Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia
This is a multicenter Phase 2, multiple dose, dose escalation study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of SPR001 in adult patients with classic congenital adrenal hyperplasia (CAH).
- Trial name
- NCT03257462
- Testing
- SPR001
- Where
- 9 sites in United States
- Volunteers
- 24 people
- Sponsor
- Spruce Biosciences
Addison Disease, Adrenal Hyperplasia Congenital
Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia
The aim of this study is to compare the effects of tablet treatment, circadian and combined circadian and ultradian subcutaneous hydrocortisone infusion on steroid metabolism and tissue responses to therapy.
- Trial name
- NCT02096510
- Testing
- Solu-Cortef, Cortef
- Where
- Norway
- Volunteers
- 8 people
- Sponsor
- Haukeland University Hospital
Congenital Adrenal Hyperplasia
Adult Height Prediction in Congenital Adrenal Hyperplasia
Congenital Adrenal Hyperplasia (CAH) is a genetic rare disease, which alters the adrenal production of gluco and mineralo corticoïds. The treatment consists in supplementing children with hydrocortisone.
- Trial name
- OPALE Model (NCT03162159)
- Testing
- Collection of growth and bone maturation data
- Where
- France
- Volunteers
- 496 people
- Sponsor
- Hospices Civils de Lyon
Polycystic Ovary Syndrome (PCOS)
Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women
The purpose of this research study is to collect specimen samples and study medical information from women with Polycystic Ovary Syndrome (PCOS) and women without PCOS.
- Trial name
- NCT01889199
- Testing
- Flutamide
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
CAH - Congenital Adrenal Hyperplasia
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia
This is a Phase 2, open-label, multiple-dose, study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NBI-74788 (crinecerfont) in pediatric participants (14 to 17 years of age) with a…
- Trial name
- NCT04045145
- Testing
- Crinecerfont
- Where
- 6 sites in United States
- Volunteers
- 8 people
- Sponsor
- Neurocrine Biosciences
Congenital Adrenal Hyperplasia
Electronic Registry of Male Patients With Congenital Adrenal Hyperplasia 21-hydroxylase Deficiency
Observational, retrospective, prospective, single-center cohort study. Participation in the registry will be offered consecutively to any patient with the disease, newly diagnosed or with documented diagnosis made at another…
- Trial name
- NCT06754423
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Polycystic Ovary Syndrome (PCOS)
Effect of Magnesium and Levocarnitine on Metabolic and Clinical Outcomes in Women With Polycystic Ovarian Syndrome (PCOS)
Polycystic Ovary Syndrome (PCOS) is one of the most common endocrine disorders among women of reproductive age and is associated with metabolic abnormalities such as insulin resistance, dyslipidemia, and hormonal imbalance, which…
- Trial name
- NCT07298564
- Testing
- Magnesium 500 mg, Levocarnitine 1000 mg
- Where
- Iran
- Volunteers
- 84 people
- Sponsor
- Behnood Abbasi
Polycystic Ovary Syndrome, c Type Natriuretic Peptide
Comparison of Serum C Type Natriuretic Peptide Levels Between Polycystic Ovary Syndrome Patients and Healthy Women
Recent studies have shown that C natriuretic peptide is produced from granulosa cells, increasing cumulative guanosine monophosphate (cGMP) production by affecting cumulus cells through natriuretic peptide receptors.
- Conditions
- Polycystic Ovary Syndrome, c Type Natriuretic Peptide, Menstrual Irregularity, Hyperandrogenism
- Trial name
- CNP (NCT04006171)
- Testing
- C type natriuretic peptide
- Where
- Cyprus
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Near East University, Turkey
Puberty, Hyperandrogenism
Assessment of Day-night Secretion of Progesterone and LH Across Puberty
Hormones are substances that are made by the body and are sent directly out into the bloodstream to increase or decrease the function of certain organs, glands, or other hormones.
- Trial name
- LH (NCT02155933)
- Testing
- Blood sampling
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Neonatal Salt Loss, Congenital Adrenal Hyperplasia (CAH)
Syndromes With Neonatal Salt Loss: Not Only Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency (21OH-ISC)
Neonatal salt loss can be caused not only by infections but also by rare endocrine disorders that resemble 21-hydroxylase deficiency but are not detected by neonatal screening.
- Trial name
- NCT07473804
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Anovulation, Polycystic Ovary Syndrome
Circulating Androgen Levels Are Not Affected by the Administration of Vaginal Micronized Progesterone for Withdrawal Bleeding in Patients With Polycystic Ovarian Syndrome
Hormonal evaluation of women who are suspected of having Polycystic ovary syndrome (PCOS) involves the measurement of basal levels of androgens and 17-hydroxyprogesterone (17-OHP), which are generally used to establish the…
- Conditions
- Anovulation, Polycystic Ovary Syndrome, Hyperandrogenism
- Trial name
- NCT03088046
- Testing
- Micronized Progesterone
- Volunteers
- 15 people
- Sponsor
- Fundacion Dexeus
Polycystic Ovary Syndrome
Environmental Factors in the Development of Polycystic Ovary Syndrome
Polycystic Ovary Syndrome (PCOS) is manifested as a heterogeneous mixture of clinical and bichemical characteristics that complicate study of its etiology.
- Trial name
- NCT00341731
- Where
- 2 sites in United States
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
Congenital Adrenal Hyperplasia
COrticosteroid in Congenital Adrenal Hyperplasia
Congenital adrenal hyperplasia (CAH) results from a deficiency of a key enzyme in the biosynthesis of cortisol, mainly 21-hydroxylase, resulting in its classic form a neonatal salt loss syndrome and / or a virilization syndrome…
- Trial name
- COCA (NCT02552251)
- Testing
- Hormonal balance measurements, metabolic balance measurements, bone balance measurements
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Caen
Primary Aldosteronism
Subtyping Primary Aldosteronism With Para-chloro-2-[18F]Fluoroethyl-etomidate
The goal of this clinical trial is to investigate the uptake characteristics of [18F]CETO in adrenal tissue in patients with two different subtypes of primary aldosteronism.
- Trial name
- SPACE (NCT06616142)
- Testing
- [18F]CETO tracer, Dexamethasone oral, Adrenal vein sampling
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- University Medical Center Groningen
Congenital Adrenal Hyperplasia
Nevanimibe HCl for the Treatment of Classic CAH
This is a multicenter, intra-subject dose-titration open-label study of nevanimibe hydrochloride (HCl) for the treatment of classic congenital adrenal hyperplasia (CAH).
- Trial name
- NCT03669549
- Testing
- Nevanimibe hydrochloride
- Where
- 11 sites in Brazil, Czechia and 3 more
- Volunteers
- 15 people
- Sponsor
- Millendo Therapeutics US, Inc.
Polycystic Ovary Syndrome (PCOS), Myo-inositol
Myo-Inositol and D-Chiro-Inositol for Menstrual Irregularities and Hormone Changes in Women With Polycystic Ovarian Syndrome
The goal of this clinical trial is to determine whether a combination of myo-inositol (MI) and D-chiro-inositol (DCI) with folic acid is more effective than placebo (Folic acid alone) in improving menstrual irregularities and…
- Conditions
- Polycystic Ovary Syndrome (PCOS), Myo-inositol, D-chiro-inositol
- Trial name
- NCT07701525
- Testing
- Myo-Inositol and D-Chiro-Inositol Combination Therapy
- Where
- Pakistan
- Volunteers
- 60 people
- Sponsor
- Nishtar Medical University
Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral)
Superselective Adrenal Arterial Embolization for Bilateral Idiopathic Hyperaldosteronism: A Prospective Cohort Study
The most common two subtypes of primary aldosteronism (PA ) are aldosterone producing adenoma (APA) and bilateral idiopathic hyperaldosteronism (IHA).
- Trial name
- SAAE-BIH (NCT05186675)
- Testing
- superselective adrenal arterial embolization
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Chronic Adrenal Insufficiency
A European Post-Authorisation Observational Study (Registry) of Patients With Chronic Adrenal Insufficiency (AI)
As a post-approval requirement of the European Medicines Agency, this European patient post authorization safety study is an observational study being conducted to monitor the safety of long-term treatment with Plenadren and…
- Trial name
- NCT01661387
- Where
- 24 sites in Germany, Italy and 3 more
- Volunteers
- 3,258 people
- Sponsor
- Shire
Congenital Adrenal Hyperplasia
Androgen Reduction in Congenital Adrenal Hyperplasia
Children with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency tend to have elevated circulating levels of androgens, which can accelerate skeletal maturation and adversely impact adult height.
- Trial name
- ARCH (NCT03548246)
- Testing
- Abiraterone acetate, Hydrocortisone, Fludrocortisone
- Where
- 4 sites in United States
- Sponsor
- University of Texas Southwestern Medical Center
Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of atumelnant (CRN04894).
- Trial name
- CALM2-CAH (NCT06712823)
- Testing
- atumelnant (CRN04894)
- Where
- 13 sites in United States, Argentina and 4 more
- Volunteers
- 200 people
- Sponsor
- Crinetics Pharmaceuticals Inc.